Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nicotine polacrilex lozenges are an important addition to our current offering of nicotine replacement therapy including nicotine transdermal system patches, sold as Habitrol® brand and various store brands.
Brand Name : Nicotine Polacrilex-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 14, 2020
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Qnovia’s RespiRx™ Inhaler IND Cleared for Smoking Cessation Therapy
Details : RespiRx is a drug device combination product that is the first truly inhalable nicotine replacement therapy (NRT) to assist smokers attempting to quit smoking.
Brand Name : RespiRx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 01, 2024
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Discovery
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : $632.9 million
Deal Type : Acquisition
Dr. Reddy's Acquire Nicotinell and Related Portfolio
Details : Through the acquisition, Reddy will leverage the NRT portfolio, which includes Nicotinell (nicotine) in various formats such as lozenges, patches, and gum, across all applicable global market.
Brand Name : Nicotinell
Molecule Type : Small molecule
Upfront Cash : $579.8 million
June 26, 2024
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Discovery
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : $632.9 million
Deal Type : Acquisition
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ayrton Announces UK MHRA Approval of Next Gen Nicotine Inhaler for Smoking Cessation
Details : MHRA approved first and only nicotine inhaler enabling rapid absorption via the lungs to help smokers replace, cut down, and ultimately quit smoking.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 25, 2024
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Perrigo Announces U.S. FDA Approval for Nicotine Coated Mint Lozenge
Details : U.S. Food and Drug Administration approved OTC, nicotine coated mint lozenges, works by reducing withdrawal symptoms in consumers who are trying to quit smoking.
Brand Name : Nicorette-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 16, 2023
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nicotine,Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CVSI-007 contains nicotine and cannabidiol which supports the cessation of smokeless tobacco use and addiction, if approved it'll be the first and only treatment for smokeless tobacco addiction.
Brand Name : CVSI-007
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 23, 2023
Lead Product(s) : Nicotine,Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Blue Ledge Capital
Deal Size : $17.0 million
Deal Type : Series A Financing
Qnovia, Inc. Raises $17 Million in Series A Funding to Advance Its Inhalable Therapeutics Pipeline
Details : The Series A proceeds will be used by Qnovia to advance its NRT drug candidate RespiRx (drud device combination having nicotine) through an IND submission with the FDA and begin human clinical trials in 2023.
Brand Name : RespiRx
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 28, 2022
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Blue Ledge Capital
Deal Size : $17.0 million
Deal Type : Series A Financing
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : With dozens of patent allowing it to control VLN (nicotine) biosynthesis in tobacco plant, Company has developed proprietary reduced nicotine content tobacco plant and cigarette, which become FDA’s Comprehensive Plan to address widespread death and dis...
Brand Name : VLN
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 07, 2022
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tobacco Leaf Protein,Nicotine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NFL Biosciences: Phase II/III Clinical Trial Launched for Smoking Cessation
Details : Company launching Phase II/III clinical trial of NFL-101, most innovative natural drug candidate in an advanced clinical development phase, could be first-line solution providing real support for people looking to stop smoking and for the treatment of th...
Brand Name : NFL-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 14, 2021
Lead Product(s) : Tobacco Leaf Protein,Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tobacco Leaf Protein,Nicotine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Diverchim S.A.
Deal Size : Undisclosed
Deal Type : Agreement
NFL Biosciences: Agreement Signed with Diverchim to Manufacture Its Active Ingredients
Details : The partnership between NFL Biosciences and Diverchim will involve manufacturing the active ingredient for NFL-101 for its use in additional clinical trials beyond the current CESTO II study (Phase II/III).
Brand Name : NFL-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 17, 2021
Lead Product(s) : Tobacco Leaf Protein,Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Diverchim S.A.
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
